G
Giuseppe Lopalco
Researcher at University of Bari
Publications - 207
Citations - 4396
Giuseppe Lopalco is an academic researcher from University of Bari. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 30, co-authored 159 publications receiving 3197 citations.
Papers
More filters
Journal ArticleDOI
Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis.
Jurgen Sota,Antonella Insalaco,Rolando Cimaz,Maria Alessio,Marco Cattalini,Romina Gallizzi,Maria Cristina Maggio,Giuseppe Lopalco,Francesco La Torre,Claudia Fabiani,M Pardeo,Alma Nunzia Olivieri,Paolo Sfriso,Carlo Salvarani,Carla Gaggiano,Salvatore Grosso,Claudia Bracaglia,Fabrizio De Benedetti,Donato Rigante,Luca Cantarini +19 more
TL;DR: In this article, the authors investigated the drug retention rate of interleukin (IL)-1 inhibitors on systemic JIA (sJIA) patients and evaluated predictive factors of drug survival based on data from a real-world setting concerning sJIA.
Journal ArticleDOI
Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.
Claudia Fabiani,Antonio Vitale,Giacomo Emmi,Giuseppe Lopalco,Lorenzo Vannozzi,Silvana Guerriero,Stefano Gentileschi,Daniela Bacherini,Rossella Franceschini,Bruno Frediani,Mauro Galeazzi,Florenzo Iannone,Gian Marco Tosi,Luca Cantarini +13 more
TL;DR: Treatment with IL-1 inhibitors is effective in the management of Behçet’s disease-related uveitis and provides a long-term control of ocular inflammation in refractory and long-lasting cases.
Journal ArticleDOI
Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases.
Giulio Cavalli,Serena Colafrancesco,Giacomo Emmi,Massimo Imazio,Giuseppe Lopalco,Maria Cristina Maggio,Jurgen Sota,Charles A. Dinarello +7 more
Journal ArticleDOI
Efficacy and safety profile of anti-interleukin-1 treatment in Behçet’s disease: a multicenter retrospective study
Giacomo Emmi,Rosaria Talarico,Giuseppe Lopalco,Rolando Cimaz,Fabrizio Cantini,Ombretta Viapiana,Ignazio Olivieri,Matteo Goldoni,Antonio Vitale,Elena Silvestri,Domenico Prisco,Giovanni Lapadula,Mauro Galeazzi,Florenzo Iannone,Luca Cantarini +14 more
TL;DR: The data have confirmed that the use of anti-IL-1β drugs is efficacious and safe with an overall acceptable retention on treatment.
Journal ArticleDOI
Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study:
Massimo Imazio,Alessandro Andreis,Gaetano M. De Ferrari,Paul Cremer,Vartan Mardigyan,Silvia Maestroni,Sushil Allen Luis,Giuseppe Lopalco,Giacomo Emmi,Dor Lotan,Renzo Marcolongo,George Lazaros,Marzia De Biasio,Luca Cantarini,Lorenzo Dagna,Andreja Cerne Cercek,Emanuele Pivetta,Beni Varma,Laeora Berkson,Enrico Tombetti,Florenzo Iannone,Domenico Prisco,Alida L.P. Caforio,Dimitrios Vassilopoulos,Dimitrios Tousoulis,Giacomo De Luca,Carla Giustetto,Mauro Rinaldi,Jae K. Oh,Allan L. Klein,Antonio Brucato,Yehuda Adler +31 more
TL;DR: In patients with recurrent pericarditis, anakinra appears efficacious and safe in reducing recurrences, emergency department admissions and hospitalisations and a full-dose treatment duration followed by a tapering period of over 3 months were the therapeutic schemes associated with a lower risk of recurrence.